Tumor Biology

, Volume 36, Issue 2, pp 807–814 | Cite as

RETRACTED ARTICLE: Correlation of IL-1F genetic polymorphisms with the risk of colorectal cancer among Chinese populations

  • Ming Ma
  • Guo-Jiang Jin
  • Ke Yun
  • Run-Qing Mu
  • Min Zhao
  • Xiao-Ou Yu
  • Shuo Wang
  • Hong Shang
Research Article


Inflammatory/immune cells have the power of infiltrating almost all human solid tumors and influencing all stages of carcinogenesis because of their stimulation of various cytokine subsets. This study aims to determine the correlation of single nucleotide polymorphisms in the IL-17F gene and the risk of colorectal cancer (CRC). One thousand patients diagnosed with CRC and a control group of 354 healthy controls were involved. Peripheral blood samples were collected. The PCR-RFLP method was used to detect the 7383A>G (rs2397084) and 7488T>C (rs763780) in the IL-17F gene. Statistical analyses were conducted with version 12.0 STATA statistical software. We found that the allele model suggested that patients carrying C allele were 1.67 times more likely to develop CRC than healthy controls (odds ratio (OR) = 1.67, 95 % confidence interval (CI) = 1.22–2.27, P = 0.001). Similarly, the homozygous and dominant models also revealed that the minor IL-17F 7488C allele conferred an increased CRC risk compared to the major T allele among our study participants (CC vs. TT: OR = 4.15, 95 % CI = 1.26–13.36, P = 0.011; TC+CC vs. TT: OR = 1.46, 95 % CI = 1.04–2.05, P = 0.027). However, all genetic models indicated that the IL-17F 7383A>G (rs2397084) polymorphism was not associated with CRC risk (all P > 0.05). The results of this study indicate that the 7488T>C (rs763780) in the IL-17F gene may be correlated with increased risk of CRC.


Interleukin-17F Colorectal cancer Single nucleotide polymorphism 



We would like to acknowledge the reviewers for their helpful comments on this paper.

Conflicts of interest



  1. 1.
    Elias D, Glehen O, Pocard M, Quenet F, Goere D, Arvieux C, et al. A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg. 2010;251(5):896–901.CrossRefPubMedGoogle Scholar
  2. 2.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMedGoogle Scholar
  3. 3.
    Shi Y, Lin H, Cui J, Qi H, Florholmen J, Liu Z, et al. The role of interleukin-17A in colorectal tumorigenesis. Cancer Biother Radiopharm. 2013;28(6):429–32.CrossRefPubMedGoogle Scholar
  4. 4.
    De Simone V, Pallone F, Monteleone G, Stolfi C. Role of T17 cytokines in the control of colorectal cancer. Oncol Immunol. 2013;2(12):e26617.Google Scholar
  5. 5.
    Astin M, Griffin T, Neal RD, Rose P, Hamilton W. The diagnostic value of symptoms for colorectal cancer in primary care: a systematic review. Br J Gen Pract. 2011;61(586):e231–43.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Adelstein BA, Macaskill P, Chan SF, Katelaris PH, Irwig L. Most bowel cancer symptoms do not indicate colorectal cancer and polyps: a systematic review. BMC Gastroenterol. 2011;11:65.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138(6):2101–14. e5.CrossRefPubMedGoogle Scholar
  8. 8.
    Watson AJ, Collins PD. Colon cancer: a civilization disorder. Dig Dis. 2011;29(2):222–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet. 2012;380(9838):219–29.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011;12(6):594–603.CrossRefPubMedGoogle Scholar
  11. 11.
    Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(7404):532–6.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Kaabachi W, Ben Amor A, Kaabachi S, Rafrafi A, Tizaoui K, Hamzaoui K. Interleukin-17A and -17F genes polymorphisms in lung cancer. Cytokine. 2014;66(1):23–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Ciric B, El-behi M, Cabrera R, Zhang GX, Rostami A. IL-23 drives pathogenic IL-17-producing CD8+ T cells. J Immunol. 2009;182(9):5296–305.CrossRefPubMedGoogle Scholar
  14. 14.
    Chen JG, Xia JC, Liang XT, Pan K, Wang W, Lv L, et al. Intratumoral expression of IL-17 and its prognostic role in gastric adenocarcinoma patients. Int J Biol Sci. 2011;7(1):53–60.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Carlson MJ, West ML, Coghill JM, Panoskaltsis-Mortari A, Blazar BR, Serody JS. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood. 2009;113(6):1365–74.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Awasthi A, Kuchroo VK. Th17 cells: from precursors to players in inflammation and infection. Int Immunol. 2009;21(5):489–98.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Rafiei A, Hosseini V, Janbabai G, Ghorbani A, Ajami A, Farzmandfar T, et al. Polymorphism in the interleukin-17A promoter contributes to gastric cancer. World J Gastroenterol. 2013;19(34):5693–9.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Iida T, Iwahashi M, Katsuda M, Ishida K, Nakamori M, Nakamura M, et al. Tumor-infiltrating CD4+ Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer. Oncol Rep. 2011;25(5):1271–7.PubMedGoogle Scholar
  19. 19.
    Zarogoulidis P, Katsikogianni F, Tsiouda T, Sakkas A, Katsikogiannis N, Zarogoulidis K. Interleukin-8 and interleukin-17 for cancer. Cancer Investig. 2014;32(5):197–205.CrossRefGoogle Scholar
  20. 20.
    Reynolds JM, Angkasekwinai P, Dong C. IL-17 family member cytokines: regulation and function in innate immunity. Cytokine Growth Factor Rev. 2010;21(6):413–23.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Pappu R, Ramirez-Carrozzi V, Sambandam A. The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases. Immunology. 2011;134(1):8–16.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 2003;14(2):155–74.CrossRefPubMedGoogle Scholar
  23. 23.
    Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity. 2011;34(2):149–62.CrossRefPubMedGoogle Scholar
  24. 24.
    Ramsey CD, Lazarus R, Camargo Jr CA, Weiss ST, Celedon JC. Polymorphisms in the interleukin 17F gene (IL17F) and asthma. Genes Immun. 2005;6(3):236–41.CrossRefPubMedGoogle Scholar
  25. 25.
    Arisawa T, Tahara T, Shibata T, Nagasaka M, Nakamura M, Kamiya Y, et al. The influence of polymorphisms of interleukin-17A and interleukin-17F genes on the susceptibility to ulcerative colitis. J Clin Immunol. 2008;28(1):44–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Yan N, Yu YL, Yang J, Qin Q, Zhu YF, Wang X, et al. Association of interleukin-17A and -17F gene single-nucleotide polymorphisms with autoimmune thyroid diseases. Autoimmunity. 2012;45(7):533–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Kawaguchi M, Takahashi D, Hizawa N, Suzuki S, Matsukura S, Kokubu F, et al. IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity. J Allergy Clin Immunol. 2006;117(4):795–801.CrossRefPubMedGoogle Scholar
  28. 28.
    Tong Z, Yang XO, Yan H, Liu W, Niu X, Shi Y, et al. A protective role by interleukin-17F in colon tumorigenesis. PLoS One. 2012;7(4):e34959.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Council for International Organizations of Medical S. International ethical guidelines for biomedical research involving human subjects. Bull Med Ethics. 2002;182:17–23.Google Scholar
  30. 30.
    Jeong TD, Cho YU, Lee W, Chun S, Min WK. An efficient genomic DNA extraction from whole blood using Nextractor. Clin Chim Acta. 2014;435:14–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Shibata T, Tahara T, Hirata I, Arisawa T. Genetic polymorphism of interleukin-17A and -17F genes in gastric carcinogenesis. Hum Immunol. 2009;70(7):547–51.CrossRefPubMedGoogle Scholar
  32. 32.
    Starnes T, Robertson MJ, Sledge G, Kelich S, Nakshatri H, Broxmeyer HE, et al. Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. J Immunol. 2001;167(8):4137–40.CrossRefPubMedGoogle Scholar
  33. 33.
    Contie M, Leger O, Fouque N, Poitevin Y, Kosco-Vilbois M, Mermod N, et al. IL-17F co-expression improves cell growth characteristics and enhances recombinant protein production during CHO cell line engineering. Biotechnol Bioeng. 2013;110(4):1153–63.CrossRefPubMedGoogle Scholar
  34. 34.
    Hizawa N, Kawaguchi M, Huang SK, Nishimura M. Role of interleukin-17F in chronic inflammatory and allergic lung disease. Clin Exp Allergy. 2006;36(9):1109–14.CrossRefPubMedGoogle Scholar
  35. 35.
    Chang SH, Dong C. IL-17F: regulation, signaling and function in inflammation. Cytokine. 2009;46(1):7–11.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Ota K, Kawaguchi M, Matsukura S, Kurokawa M, Kokubu F, Fujita J, et al. Potential involvement of IL-17F in asthma. J Immunol Res. 2014;2014:602846.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Wang L, Jiang Y, Zhang Y, Wang Y, Huang S, Wang Z, et al. Association analysis of IL-17A and IL-17F polymorphisms in Chinese Han women with breast cancer. PLoS One. 2012;7(3):e34400.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Wu X, Zeng Z, Chen B, Yu J, Xue L, Hao Y, et al. Association between polymorphisms in interleukin-17A and interleukin-17F genes and risks of gastric cancer. Int J Cancer. 2010;127(1):86–92.CrossRefPubMedGoogle Scholar
  39. 39.
    Wu D, Wu P, Huang Q, Liu Y, Ye J, Huang J. Interleukin-17: a promoter in colorectal cancer progression. Clin Dev Immunol. 2013;2013:436307.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Hundorfean G, Neurath MF, Mudter J. Functional relevance of T helper 17 (Th17) cells and the IL-17 cytokine family in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(1):180–6.CrossRefPubMedGoogle Scholar
  41. 41.
    Paradowska-Gorycka A, Wojtecka-Lukasik E, Trefler J, Wojciechowska B, Lacki JK, Maslinski S. Association between IL-17F gene polymorphisms and susceptibility to and severity of rheumatoid arthritis (RA). Scand J Immunol. 2010;72(2):134–41.CrossRefPubMedGoogle Scholar
  42. 42.
    Park H, Shin S, Park MH, Kim YS, Ahn C, Ha J, et al. Association of IL-17F gene polymorphisms with renal transplantation outcome. Transplant Proc. 2014;46(1):121–3.CrossRefPubMedGoogle Scholar
  43. 43.
    Metzger K, Fremont M, Roelant C, De Meirleir K. Lower frequency of IL-17F sequence variant (His161Arg) in chronic fatigue syndrome patients. Biochem Biophys Res Commun. 2008;376(1):231–3.CrossRefPubMedGoogle Scholar
  44. 44.
    Seiderer J, Elben I, Diegelmann J, Glas J, Stallhofer J, Tillack C, et al. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn’s disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis. 2008;14(4):437–45.CrossRefPubMedGoogle Scholar
  45. 45.
    Zhang X, Zheng L, Sun Y, Zhang X. Analysis of the association of interleukin-17 gene polymorphisms with gastric cancer risk and interaction with Helicobacter pylori infection in a Chinese population. Tumour Biol. 2014;35(2):1575–80.CrossRefPubMedGoogle Scholar
  46. 46.
    Omrane I, Baroudi O, Bougatef K, Mezlini A, Abidi A, Medimegh I, et al. Significant association between IL23R and IL17F polymorphisms and clinical features of colorectal cancer. Immunol Lett. 2014;158(1–2):189–94.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Ming Ma
    • 1
  • Guo-Jiang Jin
    • 1
  • Ke Yun
    • 1
  • Run-Qing Mu
    • 1
  • Min Zhao
    • 1
  • Xiao-Ou Yu
    • 1
  • Shuo Wang
    • 1
  • Hong Shang
    • 1
  1. 1.Department of Laboratory MedicineThe First Hospital of China Medical UniversityShenyangChina

Personalised recommendations